Valeritas

About:

Valeritas is the developer of V-GO, a disposable insulin pump, and a micro needle patch for the treatment of Type 2 diabetes.

Website: https://www.valeritas.com

Twitter/X: Valeritas_US

Top Investors: Welsh Carson Anderson & Stowe, U.S. Venture Partners, Pitango VC, MPM Capital, Abingworth

Description:

Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of the h-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes. The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes. The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs.

Total Funding Amount:

$355M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Bridgewater, New Jersey, United States

Founded Date:

2006-01-01

Contact Email:

gen-info(AT)Valeritas.com

Founders:

Robert R. Gonnelli

Number of Employees:

51-100

Last Funding Date:

2016-05-04

IPO Status:

Public

© 2025 bioDAO.ai